Companies › SciTech Development
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ST-001 nanoFenretinide (Fenretinide) Retinoid X receptor (RXR) agonist; pro-apoptotic retinoid with activity in lymphomas | RXRA, RXRB, RXRG | Phase 1 | Small Cell Lung Cancer; T-cell Lymphoma | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06922539 | ST-001 nanoFenretinide (Fenretinide) | Phase 1 | Small Cell Lung Cancer | Oncology | May 2027 |
| NCT04234048 | ST-001 nanoFenretinide (Fenretinide) | Phase 1 | T-cell Lymphoma | Oncology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.